This article is more than 5 years old. Information may no longer be current.

VIDEO: Ovarian suppression with aromatase inhibitors may improve DFS, not OS, in premenopausal women

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN ANTONIO — Ovarian function suppression with an aromatase inhibitor enhanced EFS in premenopausal women with breast cancer, Douglas Yee, MD, director of the Masonic Cancer Center, professor of medicine and pharmacology at University of Minnesota, and a HemOnc Today Editorial Board member, said at the San Antonio Breast Cancer Symposium.

However, according to a meta-analyses of ovarian suppression trials in premenopausal women, OS appeared inferior with this strategy, despite the improvement in EFS.

“Partially it could be because many of the premenopausal women are not sufficiently ovarian suppressed with the regimens we currently use,” Yee said. “We just don’t do it as a common practice, and maybe some of the women that are on ovarian suppression are actually inadequately suppressed, and that’s why they recur earlier.” – by Kristie L. Kahl

Disclosure: Yee reports no relevant financial disclosures.